Investor Overview Press Releases November 16, 2026 Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP) November 16, 2026 Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) November 12, 2026 Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference View all » Events Nov 16, 202610:30 AM GMT Jefferies Global Healthcare Conference Oct 27, 20268:00 AM EDT ATI-052 Phase 1b POC Results Update Sep 10, 20262:45 PM EDT 2026 Cantor Global Healthcare Conference View all » Feature Presentation November 2026 Corporate Presentation
November 16, 2026 Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
November 16, 2026 Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)